Biotech investors are a stubborn and hopeful lot, and many of them will never give up the ship. While confidence and patience are admirable traits up to a point, it sometimes feels like some biotech investors would spin the sun going dark as a positive, as it means no more skin cancer. In the case of Dendreon (Nasdaq:DNDN), it's only the true believers and traders who have any confidence that this company has much of a future. With another very disappointing quarter in the books, I think the only real debate left to have is whether the company can survive.

Discount Brokers Comparison: Your one-stop shop for finding the perfect broker for your investments.

Another Disappointment, Another Round Of Excuses
Disappointments have been pretty common with Dendreon and the sales of its Provenge immunotherapy, but this quarter was another bad one.

Revenue fell 18%, as Provenge sales declined 18% from the year-ago period and 21% from the prior quarter (or 17% on an adjusted basis). This is both the worst result since the third quarter of 2011 and a big (15%) miss relative to expectations.

While sales declined, the company was able to improve its margins and reduce its loss as per its previously announced cost-reduction efforts. Gross margin improved nine points (to just under 36%) and the company reduced its operating loss by more than $30 million, but much of that came from a reduction in non-cash compensation expenses.

SEE: Understanding The Income Statement

Not Winning Where It Counts?
Not surprisingly, most of the accompanying data for this quarter didn't look very positive. Management had been saying for a while that it believed it could have greater success in smaller “community” practices as opposed to larger facilities and research hospitals. Well, revenue to that category declined 16% sequentially this quarter, with an 11% decline in community oncology revenue and a 23% decline in community urology practices. In contrast, large accounts were up 15% sequentially. It's also worth noting that the company added only 33 net new accounts this quarter.

There's really nothing very new about what's wrong with Provenge. Doctors continue to elect to go with new prostate cancer therapies from Johnson & Johnson (NYSE:JNJ) (Zytiga) and Medivation (Nasdaq:MDVN) (Xtandi). As the data and labeling on these drugs continue to get better, Provenge is finding itself increasingly squeezed into a corner. Management can say what it wants to about reimbursement, calendar effects, weather or what have you, but the reality is that doctors are aware of Provenge and simply not impressed with what it can do.

Where Does Dendreon Go Now?
As befits a struggling biotech, bulls still have a few threads left to grab. Dendreon has launched a direct-to-consumer marketing campaign, and management is confident that this will lead to better sales in the second half. I don't share this confidence – there is little precedent for DTC advertising in oncology, and I really doubt that it will change prescribing habits.

I'm incrementally more positive on the company's sequencing studies with Zytiga and Xtandi. If these somehow showed meaningful improvements in outcomes, that could give some support to prescriptions and revenue. Unfortunately, it will be a while yet before that data is in hand, and there are no guarantees that it will be positive.

I'm bearish on Dendreon's prospects for achieving a level of sales that will allow for meaningful profitability. I think the company's hope of achieving year-on-year sales growth this year is slim. Likewise, I believe the company won't achieve the $100 million or so in quarterly sales I think it will need for cash flow breakeven for another three years, by which time the company's convertible debt will be a big problem.

SEE: 5 Must-Have Metrics For Value Investors

The Bottom Line
I know how biotech investing works, and I know my bearish attitude is going to attract plenty of angry bulls. That doesn't bother me, as I was bearish at $40, $14, $10, and $6 per share, and those calls have proven correct so far. While I know there will be investors who believe that the DTC campaign or European approval will turn things around, I see no reason to believe that. Likewise, I see no reason why a larger drug company would acquire this drug/company for any real amount of money, as I believe the underlying demand and profitability of Provenge just aren't good enough.

Dendreon may yet be good for multiple trading opportunities, but short-term trading is not my forte and I'll leave that discussion for others. I see fair value for Dendreon around $3 on a long-term cash flow basis and maybe $5 at most on a discounted revenue basis. While that is more than 20% above today's price, I think that's the best-case scenario and that's not nearly enough potential to account for the risks.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Insurance

    Investing Beyond Your Borders

    Investing abroad poses risks, but can also help you diversify. Discover ways to invest in foreign stocks.
  2. Mutual Funds & ETFs

    Introduction To Fundamentally Weighted Index Investing

    If you believe the market smiles on those who focus on value, growth or income, this vehicle may be for you.
  3. Retirement

    Investing Books It Pays To Read

    We provide some classic and lesser-known titles to add to your collection.
  4. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  5. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  6. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  7. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  8. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  9. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  10. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  1. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>
  2. How do I use discounted cash flow (DCF) to value stock?

    Discounted cash flow (DCF) analysis can be a very helpful tool for analysts and investors in equity valuation. It provides ... Read Full Answer >>
  3. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  4. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  5. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  6. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!